Current Report Filing (8-k)
February 27 2015 - 1:08PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): February
27, 2015
Health Discovery Corporation
(Exact name of registrant as specified in charter)
Georgia |
333-62216 |
74-3002154 |
(State of incorporation) |
(Commission File Number) |
(IRS Employer
Identification No.) |
4243 Dunwoody Club Drive, Suite 202, Atlanta
GA 30350
(Address of principal executive
offices / Zip Code)
(678) 336-5300
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o |
Written communications pursuant to Rule 425 under the Securities Act. |
|
o |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act. |
|
o |
Pre-commencement communications pursuant to Rule 14d—2(b) under the Exchange Act. |
|
o |
Pre-commencement communications pursuant to Rule 13e—4(c) under the Exchange Act. |
ITEM 8.01 Other Events
On July 17, 2013, Health
Discovery Corporation (the "Company") received a Civil Investigative Demand (the "Demand") from the Federal
Trade Commission of the United States of America (the "FTC") relating to the Company's MelApp software application. In
the Demand, the FTC has requested information relating to potentially unfair or deceptive acts or practices related to (i) false
advertising and (ii) consumer privacy and data security, in violation of Trade Commission Act, 15 U.S.C. Sections 45 and 42.
On
February 23, 2015, the FTC notified the Company of its approval, by a vote of 4-1, to accept an Agreement Containing Consent Order
(“Agreement”). This Agreement is for settlement purposes only. The Company neither admits nor denies any of
the allegations, except as specifically stated in the Agreement. The Company believes the effort to contest this matter with the
FTC would require funds greater than the Company has at its disposal.
The
Agreement will, among other things, bar the Company from claiming that any device detects or diagnoses melanoma or its risk factors,
or increases users’ chances of early detection, unless the representation is not misleading and supported by competent and
reliable scientific evidence in the form of human clinical testing of the device. The Agreement also prohibits the Company from
making any other misleading or unsubstantiated claims about a device’s health benefits or efficacy, unless the representation
is not misleading and supported by competent and reliable scientific evidence in the form of human clinical testing of the device.
Finally, the Company must pay $17,963 to the FTC.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
HEALTH DISCOVERY CORPORATION |
|
|
|
|
Dated: February 27, 2015 |
By: |
/s/ Kevin Kowbel |
|
|
|
Chairman & Interim Chief Executive Officer |
|
|
|
Health Discovery (CE) (USOTC:HDVY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Health Discovery (CE) (USOTC:HDVY)
Historical Stock Chart
From Apr 2023 to Apr 2024